#METABOLOMICS WORKBENCH siriphan_man_20250528_223857 DATATRACK_ID:5962 STUDY_ID:ST003950 ANALYSIS_ID:AN006492 PROJECT_ID:PR002474
VERSION                          	1
CREATED_ON                       	06-17-2025
#PROJECT
PR:PROJECT_TITLE                 	Plasma Metabolomic Analysis in Thai EGFR-mutated Non-Small Cell Lung Cancer
PR:PROJECT_TITLE                 	Patients
PR:PROJECT_SUMMARY               	Lung cancer remains the leading cause of cancer-related deaths worldwide,
PR:PROJECT_SUMMARY               	emphasizing an urgent need for effective, non-invasive diagnostic and prognostic
PR:PROJECT_SUMMARY               	biomarkers. Metabolic reprogramming driven by oncogenic driver alterations,
PR:PROJECT_SUMMARY               	especially EGFR mutations in non-small cell lung cancer (NSCLC), provides
PR:PROJECT_SUMMARY               	promising metabolic signatures detectable in plasma. This study aimed to
PR:PROJECT_SUMMARY               	identify plasma metabolomic biomarkers distinguishing healthy individuals from
PR:PROJECT_SUMMARY               	NSCLC patients and to further stratify NSCLC patients by EGFR mutation status
PR:PROJECT_SUMMARY               	and EGFR tyrosine kinase inhibitor (TKI) resistance. Using gas
PR:PROJECT_SUMMARY               	chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass
PR:PROJECT_SUMMARY               	spectrometry (LC-MS/MS), we quantified four groups of targeted metabolites
PR:PROJECT_SUMMARY               	(amino acids, organic acids, sugar and sugar alcohols, and phospholipids) of 78
PR:PROJECT_SUMMARY               	individuals, including NSCLC patients and healthy controls. Metabolomic
PR:PROJECT_SUMMARY               	signatures distinctly separated healthy controls from NSCLC patients and,
PR:PROJECT_SUMMARY               	furthermore, EGFR-mutated NSCLC from EGFR wild-type cases. Additionally,
PR:PROJECT_SUMMARY               	metabolomics results effectively distinguished EGFR TKI-resistant from
PR:PROJECT_SUMMARY               	treatment-naïve EGFR-mutated NSCLC. Our findings highlight the potential of
PR:PROJECT_SUMMARY               	plasma metabolites as minimally invasive biomarkers for molecular classification
PR:PROJECT_SUMMARY               	and monitoring therapeutic response in NSCLC patients.
PR:INSTITUTE                     	Mahidol University
PR:LAST_NAME                     	Khoomrung
PR:FIRST_NAME                    	Sakda
PR:ADDRESS                       	2 Wanglang road, Bangkoknoi, Bangkok 10700. Thailand.
PR:EMAIL                         	Sakda.kho@mahidol.edu
PR:PHONE                         	024195505
PR:DOI                           	http://dx.doi.org/10.21228/M8V84X
#STUDY
ST:STUDY_TITLE                   	Plasma Phospholipids Analysis in Thai EGFR-mutated Non-Small Cell Lung Cancer
ST:STUDY_TITLE                   	Patients
ST:STUDY_SUMMARY                 	Lung cancer remains the leading cause of cancer-related deaths worldwide,
ST:STUDY_SUMMARY                 	emphasizing an urgent need for effective, non-invasive diagnostic and prognostic
ST:STUDY_SUMMARY                 	biomarkers. Metabolic reprogramming driven by oncogenic driver alterations,
ST:STUDY_SUMMARY                 	especially EGFR mutations in non-small cell lung cancer (NSCLC), provides
ST:STUDY_SUMMARY                 	promising metabolic signatures detectable in plasma. This study aimed to
ST:STUDY_SUMMARY                 	identify plasma metabolomic biomarkers distinguishing healthy individuals from
ST:STUDY_SUMMARY                 	NSCLC patients and to further stratify NSCLC patients by EGFR mutation status
ST:STUDY_SUMMARY                 	and EGFR tyrosine kinase inhibitor (TKI) resistance. Using liquid
ST:STUDY_SUMMARY                 	chromatography-mass spectrometry (LC-MS/MS), we quantified 8 phospholipids of 78
ST:STUDY_SUMMARY                 	individuals, including NSCLC patients and healthy controls.
ST:INSTITUTE                     	Mahidol University
ST:LAST_NAME                     	Khoomrung
ST:FIRST_NAME                    	Sakda
ST:ADDRESS                       	2 Wanglang road, Bangkoknoi, Bangkok 10700. Thailand.
ST:EMAIL                         	siriphan.man@mahidol.edu
ST:PHONE                         	025195505
ST:SUBMIT_DATE                   	2025-05-28
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:GENDER                        	Male and female
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	C1	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=030424_015.raw
SUBJECT_SAMPLE_FACTORS           	-	C10	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=040424_042.raw
SUBJECT_SAMPLE_FACTORS           	-	C2	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=030424_021.raw
SUBJECT_SAMPLE_FACTORS           	-	C3	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=030424_046.raw
SUBJECT_SAMPLE_FACTORS           	-	C4	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=030424_038.raw
SUBJECT_SAMPLE_FACTORS           	-	C5	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=040424_066.raw
SUBJECT_SAMPLE_FACTORS           	-	C6	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=040424_076.raw
SUBJECT_SAMPLE_FACTORS           	-	C7	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=040424_023.raw
SUBJECT_SAMPLE_FACTORS           	-	C8	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=040424_029.raw
SUBJECT_SAMPLE_FACTORS           	-	C9	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	RAW_FILE_NAME(Phospholipid RAW file)=040424_051.raw
SUBJECT_SAMPLE_FACTORS           	-	B1	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_016.raw
SUBJECT_SAMPLE_FACTORS           	-	B10	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_042.raw
SUBJECT_SAMPLE_FACTORS           	-	B11	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_040.raw
SUBJECT_SAMPLE_FACTORS           	-	B12	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_043.raw
SUBJECT_SAMPLE_FACTORS           	-	B13	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_051.raw
SUBJECT_SAMPLE_FACTORS           	-	B14	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_054.raw
SUBJECT_SAMPLE_FACTORS           	-	B15	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_062.raw
SUBJECT_SAMPLE_FACTORS           	-	B16	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_057.raw
SUBJECT_SAMPLE_FACTORS           	-	B17	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_054.raw
SUBJECT_SAMPLE_FACTORS           	-	B18	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_053.raw
SUBJECT_SAMPLE_FACTORS           	-	B19	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_049.raw
SUBJECT_SAMPLE_FACTORS           	-	B2	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_031.raw
SUBJECT_SAMPLE_FACTORS           	-	B21	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_059.raw
SUBJECT_SAMPLE_FACTORS           	-	B22	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_083.raw
SUBJECT_SAMPLE_FACTORS           	-	B23	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_021.raw
SUBJECT_SAMPLE_FACTORS           	-	B24	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_039.raw
SUBJECT_SAMPLE_FACTORS           	-	B25	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_024.raw
SUBJECT_SAMPLE_FACTORS           	-	B26	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_034.raw
SUBJECT_SAMPLE_FACTORS           	-	B27	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_037.raw
SUBJECT_SAMPLE_FACTORS           	-	B28	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_027.raw
SUBJECT_SAMPLE_FACTORS           	-	B30	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_074.raw
SUBJECT_SAMPLE_FACTORS           	-	B33	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_065.raw
SUBJECT_SAMPLE_FACTORS           	-	B34	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_080.raw
SUBJECT_SAMPLE_FACTORS           	-	B42	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_064.raw
SUBJECT_SAMPLE_FACTORS           	-	B5	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_024.raw
SUBJECT_SAMPLE_FACTORS           	-	B6	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_033.raw
SUBJECT_SAMPLE_FACTORS           	-	B7	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_014.raw
SUBJECT_SAMPLE_FACTORS           	-	B8	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_029.raw
SUBJECT_SAMPLE_FACTORS           	-	B9	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_050.raw
SUBJECT_SAMPLE_FACTORS           	-	A1	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_025.raw
SUBJECT_SAMPLE_FACTORS           	-	A13	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_028.raw
SUBJECT_SAMPLE_FACTORS           	-	A14	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_023.raw
SUBJECT_SAMPLE_FACTORS           	-	A2	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_030.raw
SUBJECT_SAMPLE_FACTORS           	-	A20	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_017.raw
SUBJECT_SAMPLE_FACTORS           	-	A22	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_049.raw
SUBJECT_SAMPLE_FACTORS           	-	A23	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_052.raw
SUBJECT_SAMPLE_FACTORS           	-	A24	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_045.raw
SUBJECT_SAMPLE_FACTORS           	-	A25	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_044.raw
SUBJECT_SAMPLE_FACTORS           	-	A26	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_055.raw
SUBJECT_SAMPLE_FACTORS           	-	A27	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=030424_037.raw
SUBJECT_SAMPLE_FACTORS           	-	A28	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_025.raw
SUBJECT_SAMPLE_FACTORS           	-	A29	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_026.raw
SUBJECT_SAMPLE_FACTORS           	-	A30	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_031.raw
SUBJECT_SAMPLE_FACTORS           	-	A31	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_038.raw
SUBJECT_SAMPLE_FACTORS           	-	A32	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_040.raw
SUBJECT_SAMPLE_FACTORS           	-	A33	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_060.raw
SUBJECT_SAMPLE_FACTORS           	-	A34	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_084.raw
SUBJECT_SAMPLE_FACTORS           	-	A35	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_061.raw
SUBJECT_SAMPLE_FACTORS           	-	A36	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_047.raw
SUBJECT_SAMPLE_FACTORS           	-	A37	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_035.raw
SUBJECT_SAMPLE_FACTORS           	-	A38	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_052.raw
SUBJECT_SAMPLE_FACTORS           	-	A39	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_058.raw
SUBJECT_SAMPLE_FACTORS           	-	A40	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_071.raw
SUBJECT_SAMPLE_FACTORS           	-	A41	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_079.raw
SUBJECT_SAMPLE_FACTORS           	-	A42	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_073.raw
SUBJECT_SAMPLE_FACTORS           	-	A43	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_075.raw
SUBJECT_SAMPLE_FACTORS           	-	A45	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_050.raw
SUBJECT_SAMPLE_FACTORS           	-	A46	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	RAW_FILE_NAME(Phospholipid RAW file)=040424_070.raw
SUBJECT_SAMPLE_FACTORS           	-	D1	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=030424_022.raw
SUBJECT_SAMPLE_FACTORS           	-	D10	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=040424_069.raw
SUBJECT_SAMPLE_FACTORS           	-	D11	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=040424_078.raw
SUBJECT_SAMPLE_FACTORS           	-	D2	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=030424_027.raw
SUBJECT_SAMPLE_FACTORS           	-	D3	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=030424_047.raw
SUBJECT_SAMPLE_FACTORS           	-	D4	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=030424_039.raw
SUBJECT_SAMPLE_FACTORS           	-	D5	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=040424_030.raw
SUBJECT_SAMPLE_FACTORS           	-	D6	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=040424_033.raw
SUBJECT_SAMPLE_FACTORS           	-	D8	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=040424_041.raw
SUBJECT_SAMPLE_FACTORS           	-	D9	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	RAW_FILE_NAME(Phospholipid RAW file)=040424_048.raw
#COLLECTION
CO:COLLECTION_SUMMARY            	Blood was drawn directly into Cell-Free DNA BCT® tubes to stabilize cell-free
CO:COLLECTION_SUMMARY            	DNA. Plasma was separated from cellular components by centrifugation. For NSCLC
CO:COLLECTION_SUMMARY            	patients, plasma was first subjected to EGFR mutation analysis. Plasma aliquots
CO:COLLECTION_SUMMARY            	from all participants were stored at −80°C until subsequent analysis.
CO:SAMPLE_TYPE                   	Blood (plasma)
#TREATMENT
TR:TREATMENT_SUMMARY             	Treatment-naïve NSCLC patients had never received any systemic treatment for
TR:TREATMENT_SUMMARY             	lung cancer. EGFR TKI-resistant NSCLC patients had evidence of disease
TR:TREATMENT_SUMMARY             	progression according to the Response Evaluation Criteria In Solid Tumors
TR:TREATMENT_SUMMARY             	(RECIST) version 1.1 after receiving first- or second-generation EGFR TKI
TR:TREATMENT_SUMMARY             	treatment. All EGFR TKI-resistant NSCLC patients had acquired EGFR T790M
TR:TREATMENT_SUMMARY             	mutation.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	For phospholipids extraction, 20 µL of plasma and 20 µL of 20 µM internal
SP:SAMPLEPREP_SUMMARY            	standard (13C-PC 16:0/16:0) was added to 150 µL of methanol, vortexed 30 sec,
SP:SAMPLEPREP_SUMMARY            	and mixed with 500 µL of methyl tert-butyl ether. After shaking at 2000 rpm for
SP:SAMPLEPREP_SUMMARY            	30 min, 125 µL of MilliQ water was added. The mixture was incubated at room
SP:SAMPLEPREP_SUMMARY            	temperature for 10 min, and centrifuged at 13,800 g for 15 min at 4°C. The
SP:SAMPLEPREP_SUMMARY            	upper phase was collected, dried in a vacuum concentrator and reconstituted in
SP:SAMPLEPREP_SUMMARY            	250 µL of 60:40 acetonitrile:water containing 0.1% formic acid. Samples were
SP:SAMPLEPREP_SUMMARY            	vortex for 30 sec, sonicated for 15 min, then transferred to an LC vial.
#CHROMATOGRAPHY
CH:INSTRUMENT_NAME               	Waters Acquity I-Class
CH:COLUMN_NAME                   	Waters ACQUITY UPLC BEH HILIC (100 x 2.1 mm, 1.7 µm)
CH:COLUMN_TEMPERATURE            	55°C
CH:FLOW_GRADIENT                 	The gradient started at 60% A, decreased to 57% over 2 min, changed to 50% at
CH:FLOW_GRADIENT                 	2.10 min, decreased to 46% at 12 min, changed to 30% at 12.10 min, decreaseding
CH:FLOW_GRADIENT                 	to 1% by 18 min, returneding to 60% by 20 min, and held for 3 min (total run
CH:FLOW_GRADIENT                 	time: 23 min)
CH:FLOW_RATE                     	0.3 mL/min
CH:SOLVENT_A                     	60% Acetonitrile/40% Water; 10 mM ammonium formate ; 0.1% formic acid
CH:SOLVENT_B                     	90% Isopropanol/10% Acetonitrile; 10 mM ammonium formate; 0.1% formic acid
CH:CHROMATOGRAPHY_TYPE           	HILIC
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Waters Xevo-TQ-S
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:MS_COMMENTS                   	The MS operated in multiple reaction monitoring mode. Key parameters: capillary
MS:MS_COMMENTS                   	voltage 3.0 kV, source temperature 150°C, desolvation gas (N₂) 650 L/h at
MS:MS_COMMENTS                   	450°C, cone gas 150 L/h, nebulizer gas (Ar) 6.0 bar, collision gas 0.20 mL/min.
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	umol per dL plasma
MS_METABOLITE_DATA_START
Samples	C1	C10	C2	C3	C4	C5	C6	C7	C8	C9	B1	B10	B11	B12	B13	B14	B15	B16	B17	B18	B19	B2	B21	B22	B23	B24	B25	B26	B27	B28	B30	B33	B34	B42	B5	B6	B7	B8	B9	A1	A13	A14	A2	A20	A22	A23	A24	A25	A26	A27	A28	A29	A30	A31	A32	A33	A34	A35	A36	A37	A38	A39	A40	A41	A42	A43	A45	A46	D1	D10	D11	D2	D3	D4	D5	D6	D8	D9
Factors	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:Healthy | EGFR mutation:n/a | Treatment:n/a	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:No | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:Naïve	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	Sample source:Plasma | Disease:NSCLC | EGFR mutation:Yes | Treatment:TKI resistant	
PC 16:0/18:0	0.4461	0.3785	0.3869	0.3319	0.4533	0.4059	0.5091	0.4278	0.2838	0.4026	0.3514	0.3944	0.3074	0.3050	0.3124	0.3611	0.4126	0.4036	0.3713	0.6460	0.4120	0.3919	0.3238	0.6515	0.4509	0.4058	0.4558	0.4308	0.4530	0.2658	0.4214	0.3674	0.3094	0.2644	0.3241	0.3605	0.3988	0.4999	0.4055	0.5425	0.5251	0.3505	0.5316	0.5459	0.4885	0.3550	0.5116	0.3863	0.2904	0.3911	0.5044	0.4281	0.3931	0.4856	0.5709	0.3455	0.4855	0.2914	0.6670	0.4338	0.5550	0.4895	0.4458	0.5989	0.4508	0.5311	0.4024	0.5070	0.5626	0.4999	0.4831	0.5254	0.4005	0.5535	0.3285	0.4249	0.4761	0.4109
PC 18:0/14:0	1.0466	0.7296	0.8769	0.7344	1.0710	1.3133	1.3770	1.1746	0.7056	0.7701	1.0890	1.1578	0.9173	0.9296	1.1208	0.8640	1.0360	1.5653	1.3481	1.8066	1.9125	1.4033	1.1059	1.8999	1.3840	1.0501	1.4656	1.2131	1.5180	0.6344	1.2661	1.4555	0.7823	1.3354	0.8715	1.1993	1.2673	1.2278	1.4365	2.6621	1.4129	0.8361	1.3819	1.7863	1.3025	1.0360	1.6124	1.0584	1.2566	1.0193	1.7354	0.9154	0.9773	1.2719	1.2299	0.9948	1.6316	0.8680	1.4885	1.6184	1.3360	1.8479	1.4105	1.9853	1.0886	1.5011	1.3026	1.2801	2.0436	2.2504	1.6250	2.2251	0.9554	1.4084	0.8379	1.3444	1.2878	1.7369
PC P-18:0/18:1	0.0189	0.0195	0.0123	0.0124	0.0249	0.0405	0.0266	0.0194	0.0109	0.0233	0.0275	0.0229	0.0261	0.0211	0.0150	0.0181	0.0250	0.0536	0.0188	0.0240	0.0356	0.0210	0.0131	0.0271	0.0408	0.0364	0.0236	0.0289	0.0200	0.0156	0.0253	0.0269	0.0143	0.0145	0.0193	0.0234	0.0219	0.0309	0.0238	0.0395	0.0424	0.0081	0.0213	0.0353	0.0258	0.0168	0.0623	0.0128	0.0255	0.0123	0.0300	0.0330	0.0200	0.0176	0.0221	0.0158	0.0369	0.0291	0.0301	0.0596	0.0394	0.1003	0.0266	0.0461	0.0304	0.0431	0.0208	0.0289	0.0441	0.0495	0.0136	0.0313	0.0104	0.0140	0.0266	0.0303	0.0284	0.0258
PE 16:0/18:1	0.0636	0.0834	0.0554	0.0723	0.0588	0.0919	0.1031	0.1005	0.0508	0.0620	0.0461	0.0650	0.0718	0.0860	0.1424	0.1230	0.0373	0.1126	0.0390	0.2450	0.0583	0.0779	0.0491	0.0798	0.0526	0.1024	0.0086	0.1123	0.1078	0.0484	0.0616	0.0990	0.0978	0.3418	0.0548	0.0696	0.0900	0.1131	0.0613	0.0995	0.0878	0.0711	0.2888	0.0914	0.0475	0.0681	0.1224	0.0631	0.1055	0.0386	0.1879	0.0575	0.0503	0.0883	0.1389	0.0771	0.1070	0.0614	0.0840	0.1698	0.1319	0.1710	0.0856	0.2348	0.2328	0.1613	0.0798	0.0775	0.0829	0.1415	0.1549	0.1415	0.1303	0.1808	0.0704	0.1194	0.1010	0.0843
PE 18:0/18:2	0.7224	1.2500	0.5591	0.7203	0.8448	0.8473	1.2755	1.2306	0.6596	0.7753	0.5189	0.5218	0.7975	1.0111	1.0329	0.7531	0.4814	0.6073	0.4114	2.5758	0.4371	0.4846	0.4643	0.9603	0.6224	0.9656	0.8598	0.9803	1.3756	0.6434	0.7109	0.7538	1.1013	1.6056	0.5131	0.5565	0.5574	1.2850	0.5046	0.7921	0.7585	0.7526	3.7799	0.6916	0.4665	0.4448	1.4805	0.6760	0.6388	0.3878	1.3238	0.5203	0.7356	1.3504	1.3604	1.1791	1.0956	0.4709	0.7125	1.5391	0.7108	0.7600	0.7343	2.9804	3.9416	1.3519	0.6313	1.2663	0.8103	1.1828	0.4768	1.1983	1.1188	1.7686	0.6680	1.4140	1.0055	0.5673
PG 16:0/18:1	0.0055	0.0095	0.0060	0.0068	0.0071	0.0076	0.0076	0.0095	0.0034	0.0091	0.0078	0.0040	0.0143	0.0051	0.0046	0.0058	0.0039	0.0100	0.0031	0.0059	0.0049	0.0048	0.0081	0.0086	0.0101	0.0124	0.0121	0.0150	0.0155	0.0099	0.0059	0.0069	0.0054	0.0198	0.0049	0.0063	0.0086	0.0126	0.0045	0.0068	0.0059	0.0099	0.0154	0.0083	0.0060	0.0014	0.0044	0.0029	0.0066	0.0091	0.0073	0.0056	0.0096	0.0141	0.0074	0.0048	0.0083	0.0109	0.0091	0.0056	0.0046	0.0131	0.0093	0.0091	0.0058	0.0099	0.0059	0.0128	0.0059	0.0100	0.0089	0.0130	0.0101	0.0168	0.0115	0.0123	0.0088	0.0093
PI 18:1/18:1	0.1376	0.1293	0.0805	0.0691	0.0729	0.1436	0.2135	0.0668	0.0566	0.0679	0.0404	0.0243	0.0384	0.0556	0.0513	0.1096	0.1150	0.0496	0.0536	0.0871	0.0013	0.0269	0.0561	0.1343	0.0560	0.0760	0.0525	0.1034	0.0856	0.0510	0.0691	0.0013	0.0013	0.0450	0.0580	0.0529	0.0573	0.0969	0.1056	0.0468	0.0660	0.0560	0.1418	0.0521	0.0939	0.0393	0.0828	0.0241	0.0194	0.0320	0.0790	0.1646	0.0410	0.1665	0.1838	0.0675	0.0473	0.0285	0.0565	0.1411	0.0758	0.0520	0.0013	0.1550	0.1499	0.1089	0.0416	0.0819	0.1108	0.0714	0.0441	0.0538	0.0845	0.0775	0.0600	0.1114	0.1473	0.0279
PS 18:0/18:2	0.0069	0.0121	0.0136	0.0045	0.0055	0.0075	0.0148	0.0129	0.0120	0.0120	0.0039	0.0033	0.0041	0.0038	0.0035	0.0069	0.0034	0.0093	0.0099	0.0034	0.0063	0.0096	0.0043	0.0123	0.0049	0.0069	0.0153	0.0026	0.0055	0.0048	0.0070	0.0049	0.0090	0.0076	0.0049	0.0050	0.0053	0.0060	0.0039	0.0039	0.0071	0.0071	0.0054	0.0105	0.0069	0.0064	0.0091	0.0059	0.0059	0.0046	0.0069	0.0128	0.0059	0.0090	0.0234	0.0030	0.0054	0.0040	0.0089	0.0166	0.0131	0.0151	0.0121	0.0078	0.0081	0.0131	0.0119	0.0059	0.0108	0.0050	0.0910	0.0063	0.0113	0.0124	0.0075	0.0079	0.0104	0.0028
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	pubchem_id	inchi_key	kegg_id	other_id	other_id_type	ri	ri_type	moverz_quant	
PC 16:0/18:0	18631368								
PC 18:0/14:0	3082163								
PC P-18:0/18:1	74819089								
PE 16:0/18:1	5283496								
PE 18:0/18:2	9546749								
PG 16:0/18:1	5283509								
PI 18:1/18:1	5771759								
PS 18:0/18:2	9547091								
METABOLITES_END
#END